Bookmarks
Novel diagnostic and therapeutic pathways and improved exacerbation prediction in asthma and COPD
Safe People
University of Bristol
Academic Institute
James DoddRaquel GranellNic Timpson
Safe Projects
B3924
Respiratory disease, the third largest cause of death in England, affects one in five people. Hospital admissions for lung diseases drive NHS winter pressures, costing £11billion annually. Reducing the impact of respiratory disease and associated health inequalities is a UK Government priority (UK Life Sciences Vision 2021). In collaboration with ALSPAC we will focus on • Workstream 2: Asthma and chronic obstructive pulmonary disease (COPD)
Our research will inform later phase trials and generate evidence needed for phase 2 and 3 trials of novel therapeutics designed to alter the natural history of obstructive lung diseases and transform digital self-management. We will seek funding for these through NIHR i4i, RfPB and HTA schemes. These findings will inform clinical guidelines and national policy including clinical commissioning and NICE technology appraisals.
08/11/2021